title: A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.
abstract: Humans, in contrast to other mammals, do not synthesize N-glycolyl-neuraminic acid (Neu5Gc) due to a deletion in the gene (cmah) encoding the enzyme responsible for this conversion, the cytidine monophospho-N-acetyl-neuraminic acid hydroxylase (CMP-Neu5Ac hydroxylase). The detection of considerable amounts of Neu5Gc-sialoconjugates, in particular gangliosides, in human malignancies makes these antigens attractive targets for immunotherapy, in particular with monoclonal antibodies (mAbs). We have previously described a GM3(Neu5Gc) ganglioside-specific mAb, named 14F7, with the ability to kill tumor cells in a complement-independent manner. Silencing the cmah gene in GM3(Neu5Gc)-expressing L1210 mouse lymphocytic leukemia B cells caused the abrogation of this cytotoxic effect. We now show that cmah-silenced L1210 cells (cmah-kd) express a high level of GM3(Neu5Ac) and have an impaired ability for anchorage-independent cell growth and tumor development in vivo. No evidences of increased immunogenicity of the cmah-kd cell line were found. These results provide new evidences on the role of GM3(Neu5Gc), or Neu5Gc-sialoconjugates in general, in tumor biology. As an important tool in this study, we used the humanized version (here referred to as 7C1 mAb) of a recently described, rationally-designed mutant of 14F7 mAb that is able to bind to both GM3(Neu5Gc) and GM3(Neu5Ac). In contrast to its parental antibody, the humanized 14F7 (14F7hT) mAb, 7C1 mAb was able to kill not only GM3(Neu5Gc)-expressing L1210 wild type cells, but also GM3(Neu5Ac)-expressing cmah-kd cells, which endorses this antibody as a potential agent for cancer immunotherapy.
authors.affiliation: Immunobiology Division, Center of Molecular Immunology, P.O. Box 16040, Havana, 11600, Cuba.
authors.forename: Ana Victoria
authors.initials: AV
authors.lastname: Casadesús
authors.forename: Yuniel
authors.initials: Y
authors.lastname: Fernández-Marrero
authors.forename: Marilyn
authors.initials: M
authors.lastname: Clavell
authors.forename: José Alberto
authors.initials: JA
authors.lastname: Gómez
authors.forename: Tays
authors.initials: T
authors.lastname: Hernández
authors.forename: Ernesto
authors.initials: E
authors.lastname: Moreno
authors.forename: Alejandro
authors.initials: A
authors.lastname: López-Requena
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology; D063646:Carcinogenesis / Q000378:metabolism*; D045744:Cell Line, Tumor; D005260:Female; D005679:G(M3) Ganglioside / Q000276:immunology / Q000378:metabolism*; D057809:HEK293 Cells; D006801:Humans; D007945:Leukemia, Lymphoid / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008811:Mice, Inbred DBA; D006899:Mixed Function Oxygenases / Q000235:genetics / Q000378:metabolism; D019158:N-Acetylneuraminic Acid / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005679:G(M3) Ganglioside; D006899:Mixed Function Oxygenases; C074383:CMPacetylneuraminate monooxygenase; D019158:N-Acetylneuraminic Acid
references.citation: Breast Cancer Res Treat. 2006 Mar;96(2):115-21
references.pmid: 16322892
references.citation: Cancer Res. 2002 Jul 1;62(13):3850-4
references.pmid: 12097299
references.citation: J Natl Cancer Inst. 1987 Jan;78(1):45-54
references.pmid: 3467129
references.citation: Front Oncol. 2012 Nov 08;2:160
references.pmid: 23162791
references.citation: Hybrid Hybridomics. 2003 Aug;22(4):245-57
references.pmid: 14511570
references.citation: J Biol Chem. 1998 Dec 25;273(52):35153-60
references.pmid: 9857052
references.citation: Cancer Res. 2006 Mar 15;66(6):2937-45
references.pmid: 16540641
references.citation: Pediatr Dev Pathol. 2010 Jan-Feb;13(1):18-23
references.pmid: 19435393
references.citation: Mol Cell Biol. 2007 Jun;27(12):4340-6
references.pmid: 17420276
references.citation: Int Immunol. 2008 Apr;20(4):591-600
references.pmid: 18310617
references.citation: BMC Cancer. 2009 Jun 11;9:180
references.pmid: 19519895
references.citation: Cancer Immunol Immunother. 2004 Feb;53(2):110-7
references.pmid: 14564483
references.citation: Cancer Res. 2001 Jan 1;61(1):363-9
references.pmid: 11196188
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18936-41
references.pmid: 19017806
references.citation: Hum Vaccin. 2010 Sep 14;6(9):
references.pmid: 20855939
references.citation: Anal Chem. 2004 Apr 15;76(8):2248-55
references.pmid: 15080734
references.citation: Hybrid Hybridomics. 2002 Dec;21(6):463-8
references.pmid: 12573110
references.citation: Curr Opin Struct Biol. 2009 Oct;19(5):549-57
references.pmid: 19608407
references.citation: J Immunol. 2003 Apr 1;170(7):3488-94
references.pmid: 12646609
references.citation: Hybridoma. 1992 Apr;11(2):245-56
references.pmid: 1376720
references.citation: Expert Opin Biol Ther. 2010 Feb;10(2):153-62
references.pmid: 20088712
references.citation: J Biol Chem. 2011 Nov 25;286(47):40900-10
references.pmid: 21949119
references.citation: J Invest Dermatol. 1999 Feb;112(2):205-9
references.pmid: 9989797
references.citation: FEBS Lett. 2010 May 3;584(9):1872-8
references.pmid: 19913543
references.citation: Cancer Res. 1993 Nov 1;53(21):5244-50
references.pmid: 7916649
references.citation: Biochimie. 2003 Mar-Apr;85(3-4):455-63
references.pmid: 12770784
references.citation: J Exp Med. 2010 Aug 2;207(8):1637-46
references.pmid: 20624889
references.citation: Glycobiology. 2007 Jan;17(1):1R-13R
references.pmid: 16982663
references.citation: Clin Dev Immunol. 2010;2010:814397
references.pmid: 21048926
references.citation: Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12045-50
references.pmid: 14523234
references.citation: Scand J Immunol. 1995 Feb;41(2):148-56
references.pmid: 7863261
references.citation: Biochim Biophys Acta. 1957 Jun;24(3):604-11
references.pmid: 13436486
references.citation: Anal Chem. 2006 Feb 1;78(3):809-19
references.pmid: 16448055
references.citation: Biochim Biophys Acta. 2009 Jan;1788(1):184-93
references.pmid: 18835549
references.citation: Chem Phys Lipids. 2011 Nov;164(8):796-810
references.pmid: 21946022
references.citation: Biochem Biophys Res Commun. 2007 Feb 9;353(2):251-8
references.pmid: 17188646
references.citation: Front Oncol. 2012 Oct 23;2:150
references.pmid: 23110257
references.citation: MAbs. 2011 Nov-Dec;3(6):528-34
references.pmid: 22123064
references.citation: Hybridoma. 1995 Dec;14(6):551-6
references.pmid: 8770642
references.citation: Cancer Res. 1988 Oct 15;48(20):5680-5
references.pmid: 3167827
references.citation: Patholog Res Int. 2012;2012:235418
references.pmid: 22482082
references.citation: Anal Chem. 2010 Jun 1;82(11):4648-51
references.pmid: 20465224
references.citation: Future Oncol. 2012 Aug;8(8):943-60
references.pmid: 22894669
references.citation: Curr Opin Hematol. 2003 Jan;10(1):16-24
references.pmid: 12483107
references.citation: Clin Dev Immunol. 2011;2011:245181
references.pmid: 21941577
references.citation: Cancer Immunol Immunother. 2006 Apr;55(4):443-50
references.pmid: 16208470
references.citation: Adv Exp Med Biol. 2007;601:195-203
references.pmid: 17713006
references.citation: Adv Exp Med Biol. 2011;705:643-67
references.pmid: 21618134
references.citation: ISRN Gastroenterol. 2011;2011:645641
references.pmid: 21991524
references.citation: Cancer Res. 1985 Aug;45(8):3796-802
references.pmid: 3874688
references.citation: J Biomark. 2013;2013:602417
references.pmid: 26317019
references.citation: Cancer Biol Ther. 2008 Apr;7(4):488-95
references.pmid: 18285705
references.citation: Cancer Res. 2009 Nov 15;69(22):8662-9
references.pmid: 19903858
references.citation: J Biol Chem. 2005 Feb 11;280(6):4228-37
references.pmid: 15557321
references.citation: Cancer Res. 1996 Nov 15;56(22):5165-71
references.pmid: 8912852
references.citation: Cancer Res. 1996 Dec 1;56(23):5309-18
references.pmid: 8968075
references.citation: J Exp Clin Cancer Res. 2009 Dec 01;28:146
references.pmid: 19951433
references.citation: In Vivo. 2012 Jul-Aug;26(4):609-17
references.pmid: 22773575
references.citation: Glycobiology. 2008 Oct;18(10):818-30
references.pmid: 18669916
references.citation: Mol Immunol. 2011 Apr;48(8):1059-67
references.pmid: 21306777
references.citation: Cancer Res. 1986 Nov;46(11):5541-7
references.pmid: 3489524
references.citation: Hybridoma. 2000 Dec;19(6):463-71
references.pmid: 11152398
references.citation: Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16204-9
references.pmid: 15534203
references.citation: FEBS Lett. 2010 May 3;584(9):1901-6
references.pmid: 19874824
references.citation: J Clin Oncol. 2003 Mar 15;21(6):1015-21
references.pmid: 12637465
references.citation: Front Oncol. 2012 Dec 20;2:195
references.pmid: 23267436
references.citation: Cell Death Differ. 2009 Jan;16(1):164-74
references.pmid: 18820643
references.citation: Mol Cancer Ther. 2008 Jul;7(7):2033-41
references.pmid: 18645013
references.citation: Immunobiology. 2011 Dec;216(12):1239-47
references.pmid: 21802167
references.citation: Hybrid Hybridomics. 2003 Aug;22(4):235-43
references.pmid: 14511569
references.citation: Glycoconj J. 2009 Apr;26(3):231-45
references.pmid: 18777136
references.citation: Cancer Detect Prev. 2002;26(2):114-20
references.pmid: 12102145
references.citation: Oral Dis. 2012 Nov;18(8):741-7
references.pmid: 22574836
references.citation: J Biol Chem. 2012 Aug 17;287(34):28852-64
references.pmid: 22692204
references.citation: Glycoconj J. 2012 Dec;29(8-9):627-37
references.pmid: 22610315
references.citation: Glycobiology. 2010 Jan;20(1):62-77
references.pmid: 19759399
references.citation: Eur J Biochem. 1979 Feb 15;94(1):19-23
references.pmid: 436839
references.citation: Hum Vaccin Immunother. 2013 Jun;9(6):1237-40
references.pmid: 23442598
references.citation: Immunology. 2009 Sep;128(1 Suppl):e641-51
references.pmid: 19740325
references.citation: ISRN Dermatol. 2011;2011:848909
references.pmid: 22363862
references.citation: Cancer Sci. 2013 Jan;104(1):43-7
references.pmid: 23004020
references.citation: Clin Exp Immunol. 2012 Feb;167(2):206-15
references.pmid: 22235996
references.citation: Front Physiol. 2010 Nov 19;1:153
references.pmid: 21423393
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: J Biol Chem. 1998 Jun 19;273(25):15866-71
references.pmid: 9624188
references.citation: Hybridoma. 2000 Jun;19(3):241-7
references.pmid: 10952412
references.citation: ACS Chem Biol. 2013 Feb 15;8(2):376-86
references.pmid: 23138862